FDA approves landmark pancreatic cancer drug that’s shown to improve survival

Live updates

1. 4d ago

   FDA Approves Daily Pill for Advanced Pancreatic Cancer

   The Food and Drug Administration recently authorized a daily pill designed to treat pancreatic cancer patients. The medication targets adults diagnosed with metastatic pancreatic adenocarcinoma and is produced as an oral multi-selective RAS(ON) inhibitor developed by RevMed, known as daraxonrasib. Clinical data indicates the treatment can nearly double survival rates for individuals with this advanced form of the disease. Former University of Florida President Sasse and other patients have credited the medication with extending their lives. Early study findings also suggest potential benefits for lung cancer patients.

   Why it matters

   Pancreatic cancer remains one of the most challenging malignancies to treat, making targeted therapies a critical advancement for patients. Daraxonrasib represents a new approach by utilizing an oral multi-selective RAS(ON) inhibitor. The Food and Drug Administration authorization offers a daily pill option for individuals battling metastatic pancreatic adenocarcinoma.

   What is confirmed

   • The Food and Drug Administration approved a new daily pill drug for pancreatic cancer patients.
   • The medication daraxonrasib is an oral multi-selective RAS(ON) inhibitor developed by RevMed.
   • The drug was authorized for adults diagnosed with metastatic pancreatic adenocarcinoma.
   • Clinical data shows the medication can nearly double survival rates for patients with this disease.
   • Patients including former University of Florida President Sasse have credited the drug with extending their lives.

   Still unconfirmed

   • Early study findings indicate the medication may also offer potential benefits for lung cancer patients.

   What to watch next

   • Further clinical data regarding the drug's effectiveness for lung cancer patients
   • Additional updates on patient outcomes and accessibility following the Food and Drug Administration approval
   Sources used for this update (4)

   1. www.etvbharat.com — Can Stress Actually Cause Cancer, Or Is That Just Something People Say? Oncologist Responds
   2. www.yahoo.com — FDA approves new drug for pancreatic cancer. Who’s eligible and how does it work?
   3. finance.yahoo.com — New Multi-Site Validation Study Published by Panakeia Reinforces Scalability of AI Multi-Omics Platform
   4. www.wbaltv.com — Routine blood testing may hold hidden clues to colorectal cancer before age 45
   confidence 100%
2. 11d ago

   Approved Pancreatic Cancer Drug Shows Early Promise for Lung Cancer

   A newly approved medication that targets advanced pancreatic cancer may also offer potential benefits for lung cancer patients, according to early study findings. The Food and Drug Administration previously authorized daraxonrasib, an oral multi-selective RAS(ON) inhibitor developed by RevMed, for adults diagnosed with metastatic pancreatic adenocarcinoma. Clinical data indicates the drug can nearly double survival rates for individuals with this form of the disease. Patients, including former University of Florida President Sasse, have credited the medication with extending their lives.

   Why it matters

   The Food and Drug Administration authorized daraxonrasib for patients who previously underwent at least one systemic therapy or lacked options for multiagent systemic therapy. The medication works by blocking specific proteins that drive tumor growth. Further investigation into its effectiveness against other malignancies could expand treatment options.

   What is confirmed

   • The Food and Drug Administration approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor developed by RevMed, for adults with metastatic pancreatic adenocarcinoma.
   • Clinical data indicates the drug can nearly double survival rates for metastatic pancreatic adenocarcinoma.
   • A new study suggests the pancreatic cancer drug may hold promise for lung cancer as well.

   What to watch next

   • Results from formal clinical trials testing daraxonrasib on lung cancer patients
   • Data on whether the drug can effectively target tumor-driving proteins in other types of cancer
   Sources used for this update (5)

   1. www.coloradopolitics.com — House passes stopgap funding bill with help of 176 Democrats to avoid pre-election shutdown
   2. abcnews.com — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
   3. www.wvgazettemail.com — USS Lincoln crew hits the streets of Thai beach city after lengthy Middle East deployment
   4. www.news-medical.net — New study uncovers bacterial route to testosterone production
   5. www.news-medical.net — Tumor environments sculpt diverse natural killer cells for cancer therapies
   confidence 95%
3. 15d ago

   FDA approves daraxonrasib for metastatic pancreatic cancer

   The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. The drug is authorized for patients who have already undergone at least one prior systemic therapy or those who are not candidates for multiagent systemic therapy. Developed by RevMed, the medication blocks proteins that drive tumor growth. Clinical data indicates the drug can nearly double survival rates for this form of cancer. Patients including former UF President Sasse have credited the pill with extending their lives.

   Why it matters

   Pancreatic cancer is one of the deadliest cancer forms. This approval follows a landmark clinical trial led by Dana-Farber. The drug provides a new option for patients whose cancer has spread and continued to progress despite previous treatments.

   What is confirmed

   • The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma.
   • The medication is an oral multi-selective RAS(ON) inhibitor.
   • The drug is for patients who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
   • The drug is for patients whose pancreatic cancer has spread to other parts of the body and progressed despite previous treatment.

   What to watch next

   • Publication of full results from the Dana-Farber clinical trial
   • Insurance coverage determinations for daraxonrasib
   Sources used for this update (5)

   1. www.news-medical.net — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
   2. www.news-medical.net — FDA approves daraxonrasib for patients with metastatic pancreatic cancer
   3. www.denverpost.com — Federal grant cuts hit Colorado studies to make healthcare more efficient
   4. www.coloradopolitics.com — Trump promises retaliation for Iran attacks: ‘We’re going to hit them hard’
   5. www.coloradopolitics.com — Trump says communities that don’t build data centers will be ‘backwards and poor’
   confidence 100%
4. 18d ago

   FDA Approves Rasonque Pill for Advanced Pancreatic Cancer

   The FDA approved Rasonque (daraxonrasib), a daily oral RAS inhibitor, for adults with advanced pancreatic cancer. Developed by RevMed, the medication blocks a protein that drives tumor growth. Clinical data indicates the drug can nearly double patient survival rates for one of the deadliest cancer forms. Patients including former UF President Sasse and a stage 4 patient in Maine have credited the pill with extending their lives.

   Why it matters

   Metastatic pancreatic cancer has historically offered patients limited treatment options and short survival windows. This approval introduces the first pill specifically designed to extend survival in these cases.

   What is confirmed

   • The FDA approved Rasonque for adults with advanced pancreatic cancer.
   • Rasonque is a daily oral pill.
   • The drug functions as a RAS inhibitor.

   Still unconfirmed

   • Rasonque can nearly double patient survival rates.
   • Former UF President Sasse and a patient in Maine credit the drug with extending their lives.

   What to watch next

   • Long-term survival data from the global clinical trial.
   • Insurance coverage and accessibility updates for Rasonque.
   Sources used for this update (4)

   1. medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
   2. apnews.com — Live updates: Iran war reaches its six-month mark as Trump turns focus to increasing economic pressure
   3. www.gastroenterologyadvisor.com — FDA Approves First Pill to Extend Survival In Advanced Pancreatic Cancer
   4. www.coloradopolitics.com — House will vote to denounce socialism
   confidence 90%
5. 18d ago

   FDA Approves RASONQUE for Advanced Pancreatic Cancer

   The FDA approved RASONQUE (daraxonrasib) on Wednesday to treat advanced pancreatic cancer. The once-daily pill blocks a protein that drives tumor growth and has shown the ability to nearly double patient survival rates. The drug is developed by RevMed and targets one of the deadliest forms of cancer. Early reports include a patient in Maine with stage 4 cancer and former UF President Sasse, who both credit the medication with extending their lives.

   Why it matters

   Pancreatic cancer is notoriously difficult to treat and often has low survival rates. This approval introduces a targeted approach to managing the disease. The drug's success may position RevMed as a major player in oncology.

   What is confirmed

   • The FDA approved RASONQUE (daraxonrasib) on Wednesday for advanced pancreatic cancer.
   • The drug is a once-daily pill that blocks a protein driving tumor growth.
   • Clinical data indicates the treatment nearly doubles patient survival rates.

   Still unconfirmed

   • RevMed could become the next oncology titan following the Rasonque approval.
   • Questions linger on the ground as RevMed prepares for the drug launch.

   What to watch next

   • Availability and pricing details for RASONQUE
   • Long-term survival data from expanded patient groups
   • Development of similar protein-blocking medicines
   Sources used for this update (14)

   1. The Washington Post — FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
   2. Pancreatic Cancer Action Network — FDA Approves RASONQUE™ (daraxonrasib)
   3. The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
   4. STAT — Pharmalittle: We're reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more
   5. Fierce Pharma — As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground
   6. www.forbes.com — Forbes Daily: Nvidia Beats Expectations As Data Center Business Grows
   7. BioSpace — RevMed could become ‘next oncology titan’ with Rasonque nod
   8. www.today.com — FDA Approves ‘Game-Changing’ Pancreatic Cancer Drug
   9. NPR — New FDA-approved drug offers hope in pancreatic cancer treatment : Here & Now Anytime
   10. www.yahoo.com — Groundbreaking pancreatic cancer drug approved by FDA: What we know
   11. www.usatoday.com — FDA approves pancreatic cancer drug Sasse credits with extending his life
   12. www.yahoo.com — FDA approves landmark pancreatic cancer drug that’s shown to improve survival
   confidence 95%
6. 19d ago

   FDA Approves Daraxonrasib for Pancreatic Cancer Treatment

   The FDA has approved daraxonrasib, a once-daily pill designed to treat pancreatic cancer. The drug works by blocking a protein that drives tumor growth in most cases. Clinical data indicates the treatment nearly doubles patient survival rates. This approval introduces a new approach to managing a deadly disease, with some patients, including one with stage 4 cancer in Maine, reporting that the medication is extending their lives.

   Why it matters

   Pancreatic cancer is known as a deadly disease with historically limited treatment options. This drug targets a specific protein fueling tumors in the vast majority of cases. The approval represents a shift in care for patients facing this diagnosis.

   What is confirmed

   • The FDA approved the drug daraxonrasib to treat pancreatic cancer.
   • The medication is a once-daily pill.
   • The drug improves survival rates for patients.

   Still unconfirmed

   • Patient survival rates nearly double with the use of this pill.
   • The drug blocks a protein that fuels tumor growth in the vast majority of cases.
   • A stage 4 cancer patient in Maine says the pill is buying him time.

   What to watch next

   • Publication of full clinical trial data regarding survival rate increases.
   • Insurance coverage and accessibility reports for daraxonrasib.
   Sources used for this update (8)

   1. WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
   2. The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
   3. Fox News — FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
   4. AP News — FDA approves landmark pancreatic cancer drug that’s shown to improve survival
   5. BBC — FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer
   6. WGME — Stage 4 Maine cancer patient says new FDA-approved pill is buying him time
   7. CBS News — FDA approves new pancreatic cancer drug that could extend patients' lives
   8. www.boisestatepublicradio.org — FDA approves landmark pancreatic cancer drug that's shown to improve survival
   confidence 90%